GSA Capital Partners LLP Acquires 18,616 Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

GSA Capital Partners LLP increased its stake in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 129.6% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 32,979 shares of the company’s stock after purchasing an additional 18,616 shares during the period. GSA Capital Partners LLP’s holdings in EyePoint Pharmaceuticals were worth $264,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. ProShare Advisors LLC bought a new stake in shares of EyePoint Pharmaceuticals in the first quarter worth $209,000. Vanguard Group Inc. grew its stake in shares of EyePoint Pharmaceuticals by 17.8% during the 1st quarter. Vanguard Group Inc. now owns 2,396,228 shares of the company’s stock valued at $49,530,000 after purchasing an additional 362,168 shares during the period. American International Group Inc. increased its position in shares of EyePoint Pharmaceuticals by 38.4% during the 1st quarter. American International Group Inc. now owns 18,378 shares of the company’s stock valued at $380,000 after purchasing an additional 5,101 shares during the last quarter. Janus Henderson Group PLC bought a new position in shares of EyePoint Pharmaceuticals in the 1st quarter worth approximately $555,000. Finally, California State Teachers Retirement System boosted its holdings in shares of EyePoint Pharmaceuticals by 884.2% in the first quarter. California State Teachers Retirement System now owns 43,275 shares of the company’s stock worth $894,000 after buying an additional 38,878 shares during the last quarter. Institutional investors own 99.41% of the company’s stock.

EyePoint Pharmaceuticals Stock Performance

Shares of EYPT opened at $8.95 on Friday. The company has a 50 day moving average price of $9.77 and a 200-day moving average price of $9.54. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $5.86 and a fifty-two week high of $30.99. The stock has a market capitalization of $610.84 million, a PE ratio of -4.48 and a beta of 1.50.

Analyst Upgrades and Downgrades

A number of analysts have commented on EYPT shares. Scotiabank initiated coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, October 16th. They set a “sector outperform” rating and a $18.00 target price for the company. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a research report on Saturday, September 21st. HC Wainwright reduced their price target on EyePoint Pharmaceuticals from $30.00 to $22.00 and set a “buy” rating for the company in a research report on Monday, November 11th. Robert W. Baird lowered their price objective on EyePoint Pharmaceuticals from $38.00 to $33.00 and set an “outperform” rating on the stock in a research report on Monday, November 11th. Finally, Jefferies Financial Group assumed coverage on shares of EyePoint Pharmaceuticals in a report on Wednesday, August 28th. They issued a “buy” rating and a $15.00 target price for the company. One investment analyst has rated the stock with a sell rating and nine have given a buy rating to the company. According to data from MarketBeat, EyePoint Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.00.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.